AbbVie (NYSE:ABBV) reported positive topline Phase 1 results for ABBV-295, a long-acting amylin analog for obesity treatment.

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

AbbVie announced this morning it would buy clinical-stage biotech company Capstan Therapeutics for up to $2.1 billion in cash, picking up the company's in vivo CAR-T therapy candidate. San Diego-based ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody ...

AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor. Upper limb essential ...

NORTH CHICAGO, Ill., Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. Robert A. Michael, president and ...

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a ...